Financial Performance - The company's operating revenue for 2022 reached ¥476,821,312.39, representing a year-on-year increase of 53.97%[24]. - Net profit attributable to shareholders increased by 55.07% to ¥182,569,601.64, while the net profit excluding non-recurring gains and losses rose by 79.44% to ¥168,680,318.38[24][27]. - The cash flow from operating activities remained stable, with a net amount of ¥104,375,771.45, showing a slight increase of 0.36% compared to the previous year[24][27]. - Total assets grew by 17.92% to ¥1,393,534,642.98, and net assets attributable to shareholders increased by 11.75% to ¥1,219,243,201.94[24][27]. - Basic earnings per share rose to ¥2.10, reflecting a 48.94% increase from the previous year[25]. - The company's operating income for the fourth quarter was 137,148,352.30 RMB, while the net profit attributable to shareholders was 42,692,243.69 RMB, indicating a stable performance despite fluctuations in net profit due to factors such as share-based payments and exchange rate losses[30][31]. Dividend and Capital Structure - The company plans to distribute a cash dividend of RMB 8.00 per 10 shares, totaling RMB 69,314,761.60 (including tax) based on the remaining shares after buybacks[5]. - The company intends to increase its capital reserve by issuing 4 additional shares for every 10 shares held, resulting in an increase of 34,657,381 shares, raising the total share capital to 121,637,381 shares[5]. - The company has not experienced any changes in its total share capital from the announcement date to the equity distribution registration date[6]. Audit and Governance - The company has received a standard unqualified audit report from Ernst & Young Hua Ming[5]. - The board of directors has confirmed the authenticity, accuracy, and completeness of the annual report[4]. - The company has not reported any non-operational fund occupation by controlling shareholders or related parties[9]. - The company has not violated any decision-making procedures for external guarantees[9]. - The company has not disclosed any special arrangements for corporate governance[9]. - The company emphasizes that forward-looking statements regarding future plans and strategies do not constitute a commitment to investors[8]. Research and Development - The company's R&D expenditure accounted for 12.56% of operating revenue, a decrease of 0.79 percentage points compared to 2021[25]. - Research and development investment in 2022 was 59.90 million yuan, a 44.88% increase from the previous year, constituting 12.56% of operating revenue[40]. - The company applied for 42 new patents and obtained 33 new patents during the reporting period[118]. - The company has a cumulative total of 156 patent applications, with 96 patents granted, reflecting its commitment to innovation[119]. - The company has developed a dual-channel 3D fluorescence endoscope technology suitable for 10mm laparoscopic systems, enhancing surgical capabilities[115]. Market and Sales - The company achieved dual growth in both domestic and international markets while expanding its optical business and related products alongside the rapid growth of its medical endoscope business[38]. - The company plans to increase the promotion of its complete system products domestically, despite facing competition from established imported brands[136]. - The total sales revenue for the top five customers reached 375.19 million RMB, accounting for 78.69% of the annual sales total[157]. - Sales to Customer 1 amounted to 295.44 million RMB, representing 61.96% of the annual sales total, with a year-on-year increase of 67.41%[158]. Production and Supply Chain - The company has increased inventory to mitigate the impact of extended delivery times due to global supply chain disruptions[54]. - The company implements a supply chain management system that includes supplier grading and continuous evaluation to ensure quality[51]. - The production of medical endoscopes follows ISO 13485 standards, ensuring compliance with quality management requirements[54]. - The company has seen an increase in procurement from new suppliers due to increased production of new products[163]. Technological Innovation - The company has established four core technology platforms: optical technology, precision machinery technology, electronic technology, and digital image technology[76]. - The company has successfully implemented multi-spectral LED illumination technology in endoscope systems, which can also be extended to clinical diagnostic applications[81]. - The company has developed a leading fluorescence endoscope that integrates fluorescence technology with endoscopic technology, opening new applications in the medical field[74]. - The company is integrating deep learning-based intelligent image recognition technology into its next-generation intelligent surgical endoscope system[75]. Future Plans - The company plans to accelerate the development of medical endoscope series products to expand its existing product line[182]. - The company aims to enhance its competitive edge in fluorescence endoscope products by continuously upgrading existing models and developing new ones[184]. - The company is committed to strengthening talent development and improving employee cohesion through a competitive compensation system[192]. - The company will complete the registration and launch of the second generation 4K fluorescence endoscope imaging system and fog-free imaging system, establishing a nationwide distribution channel[194].

Financial Performance - The company's operating revenue for 2022 reached ¥476,821,312.39, representing a year-on-year increase of 53.97%[24]. - Net profit attributable to shareholders increased by 55.07% to ¥182,569,601.64, while the net profit after deducting non-recurring gains and losses rose by 79.44% to ¥168,680,318.38[24]. - The cash flow from operating activities remained stable, with a net amount of ¥104,375,771.45, showing a slight increase of 0.36% compared to the previous year[24]. - Total assets increased by 17.92% to ¥1,393,534,642.98, and net assets attributable to shareholders rose by 11.75% to ¥1,219,243,201.94[24]. - The basic earnings per share for 2022 was ¥2.10, reflecting a growth of 48.94% compared to the previous year[25]. - The company's operating income for the fourth quarter was 137,148,352.30 RMB, while the net profit attributable to shareholders was 42,692,243.69 RMB, indicating a stable profit despite fluctuations in operating income[30]. - The net profit attributable to shareholders for the third quarter was 60,007,924.16 RMB, reflecting strong performance in that period[30]. - The company reported a total revenue of 130.9 million RMB, with a net profit of 59.9 million RMB, reflecting a significant increase in performance compared to the previous year[125]. Research and Development - The company's R&D investment as a percentage of operating revenue was 12.56%, a decrease of 0.79 percentage points from the previous year[25]. - The company's R&D investment in 2022 was 59.90 million yuan, a 44.88% increase from 41.34 million yuan in the previous year, accounting for 12.56% of operating revenue[40]. - The company has established a clear R&D project mechanism to ensure the continuous development of innovative products and technologies[48]. - The company has developed a non-contact, high-precision palm vein recognition identity authentication product with a recognition rate of 99.99% and a false recognition rate of only 0.00001%[66]. - The company has filed 42 new patent applications and received 33 new patent grants during the reporting period, indicating strong innovation activity[118]. - The company has established a comprehensive R&D team with expertise in optics, precision machinery, automation, and software, aiming to improve overall human resource quality[193]. Product Development and Innovation - The first-generation 4K fluorescence imaging system received product registration and was launched for clinical use during the reporting period, laying the foundation for market sales and product iteration[38]. - The company is expanding its product line in the medical optical imaging field, including 4K fluorescence/white light laparoscopes and various endoscopes, with ongoing development of multiple products to enhance market presence[42]. - The company has successfully developed a remote rehabilitation device that received registration certification on March 11, 2023, indicating progress in telemedicine[125]. - The company is actively developing 4K ultra-high-definition endoscope products across various departments, with the 4K ultra-high-definition fluorescence laparoscope already registered[184]. - The company is focusing on the development of consumer-grade palm vein modules to meet diverse customer needs and promote the application of palm vein technology[194]. Market Expansion and Sales - The company achieved dual growth in both domestic and international markets while expanding its optical business and related products alongside the medical endoscope business[38]. - The company plans to enhance its marketing network and information technology projects to improve market share and sales capabilities in the domestic market[136]. - The company has established 7 marketing network centers in Shandong province to cover most medical institutions in the area[136]. - The company is exploring the establishment of final assembly and repair lines in the United States to mitigate international trade risks[141]. - Domestic sales revenue increased by 77.86%, contributing to a 3.18% rise in its share of total revenue, driven by the expansion of the domestic marketing system[150]. Corporate Governance and Compliance - The company has received a standard unqualified audit report from Ernst & Young Hua Ming[5]. - The company has not reported any non-operational fund occupation by controlling shareholders or related parties[9]. - The company has not violated any decision-making procedures for external guarantees[9]. - The company has not experienced any instances where more than half of the board members could not guarantee the accuracy and completeness of the annual report[9]. - The company has established a comprehensive quality management system, achieving certifications from NMPA, FDA, CE, MFDS, and INMETRO, ensuring compliance with global quality standards[134]. Financial Management - The company has a dependency on a limited number of customers, with one customer accounting for over 50% of total sales, indicating a risk in customer concentration[159]. - The accounts receivable increased by 83.06% to 1.14 billion RMB due to higher sales revenue during the reporting period[167]. - Inventory rose by 108.66% to 138.01 million RMB as the company increased material procurement reserves in response to market conditions and expanded production scale[169]. - The company reported a significant increase in prepayments, which rose by 145.78% to 66.42 million RMB, attributed to material procurement and software development[167]. - The company reported a 200.06% increase in taxes payable, amounting to RMB 21,568,078.86, primarily due to increased profits and corporate income tax obligations[170]. Strategic Partnerships - The company has established a long-term partnership with US medical device giant Stryker, contributing to the development of core optical components for endoscope systems[64]. - The company signed a major sales contract with Stryker, with a total contract value of ¥385,982,657.13, of which ¥108,618,939.57 has been fulfilled[154]. - The company is actively pursuing partnerships with hospitals and research institutions to enhance R&D capabilities and accelerate product development[49]. Risk Management - There are no significant risks that could materially affect the company's operations during the reporting period[4]. - The company is actively managing risks related to international trade and currency fluctuations to protect its business operations[140].

Financial Performance - The company's operating revenue for Q1 2023 reached ¥148,428,523.74, representing a year-on-year increase of 58.76%[4] - Net profit attributable to shareholders was ¥48,464,088.23, up 35.40% year-on-year, while the net profit excluding non-recurring gains and losses increased by 38.45%[6] - Total revenue for Q1 2023 reached RMB 148,428,523.74, a significant increase of 58.8% compared to RMB 93,489,632.76 in Q1 2022[20] - Net profit for Q1 2023 was RMB 47,706,648.48, representing a growth of 34.0% from RMB 35,609,101.09 in Q1 2022[21] - The company's total revenue for Q1 2023 was ¥62,700,194.25, a 96% increase from ¥32,019,026.46 in Q1 2022[26] - The net profit attributable to the parent company was ¥48,119,272.38, compared to ¥35,401,219.15 in the same period last year, reflecting a growth of approximately 36%[22] - The company reported a total profit of 33,289,165.08 RMB in Q1 2023, down from 39,629,682.06 RMB in Q1 2022, representing a decrease of about 16.5%[27] - The company’s net profit for Q1 2023 was 33,913,075.60 RMB, compared to 39,554,279.81 RMB in Q1 2022, marking a decrease of approximately 14.2%[27] Research and Development - The company's R&D investment totaled ¥17,142,509.37, marking a significant increase of 61.26% compared to the same period last year, accounting for 11.55% of operating revenue[5] - Research and development expenses increased to RMB 17,142,509.37 in Q1 2023, a rise of 61.5% compared to RMB 10,630,408.34 in Q1 2022[20] Cash Flow and Liquidity - Cash received from sales amounted to ¥144,082,100, an increase of 53.25% year-on-year, although net cash flow from operating activities decreased by 23.33%[6] - Cash inflow from operating activities totaled ¥154,311,431.44, up from ¥101,078,683.79 in Q1 2022, marking a 52.6% increase[22] - The net cash flow from operating activities was ¥17,993,727.64, down from ¥23,469,085.19 in the previous year, indicating a decrease of 23.5%[22] - The company reported a net cash outflow from investing activities of ¥84,405,259.84, an improvement from a net outflow of ¥427,691,546.92 in Q1 2022[22] - Cash and cash equivalents decreased to RMB 568,106,391.00 from RMB 636,150,039.18 at the end of 2022[19] - Cash and cash equivalents at the end of Q1 2023 totaled 302,366,859.53 RMB, down from 395,801,944.38 RMB at the beginning of the quarter[30] Expenses and Costs - The company's sales costs increased by 63.28%, primarily due to the rise in sales revenue[10] - Management expenses rose by 55.44%, driven by increased personnel costs and depreciation of fixed assets[10] - Operating costs for Q1 2023 amounted to RMB 91,055,804.33, up 71.1% from RMB 53,194,317.21 in the same period last year[20] - Cash paid for purchasing goods and services surged by 96.46% as the company continued to expand production and increase material reserves[11] - Cash paid for taxes increased by 204.17% due to higher sales revenue and the payment of deferred taxes from the previous year[11] - Tax expenses rose by 48.17% primarily due to increased sales and profits leading to higher corporate income tax provisions[11] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,404,531,032.78, a slight increase of 0.79% from the end of the previous year[5] - The company's total assets as of March 31, 2023, were RMB 1,404,531,032.78, up from RMB 1,393,534,642.98 at the end of 2022[19] - The total liabilities decreased to RMB 126,444,870.54 as of March 31, 2023, from RMB 171,048,771.88 at the end of 2022[19] - The company's total liabilities decreased to ¥121,864,630.85 from ¥181,857,440.84, a reduction of approximately 32.9%[25] - The equity attributable to shareholders increased to RMB 1,275,308,816.90 as of March 31, 2023, compared to RMB 1,219,243,201.94 at the end of 2022[19] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 5,080[13] - The company's basic and diluted earnings per share were both ¥0.56, reflecting a year-on-year increase of 36.59%[4] - Basic and diluted earnings per share increased to ¥0.56 from ¥0.41, representing a 36.6% rise year-over-year[22]

股票代码：688677 股票简称：海泰新光 公告编号：2023-014 青岛海泰新光科技股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心音频直播和网络互动 投资者可于 2023 年 04 月 14 日(星期五) 至 04 月 20 日(星期四)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 investment@novelbeam.com 进行提问。公司将在说明会上对投资者普遍关注的 问题进行回答。 青岛海泰新光科技股份有限公司（以下简称"公司"）将于 2023 年 4 月 21 日发布公司 2022 年度报告，为便于广大投资者更全面深入地了解公司 2022 年度经营成果、财务状况，公司计划于 2023 年 04 月 21 日 下午 15:00-16:30 举行 2022 年度业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 本 ...

海泰新光 2022 年 4 月份投资者调研记录 Q：疫情对物流、人员、上游供应链、出口是否有影响？公司是否有针对疫情方面的应对策 略？ 这两年来疫情一直不停反复，针对主要的影响因素，公司也做了一些相应的准备，如： （1）去年开始供应链就已面临困难，采购周期变长，公司在去年开始已对重要的生产材料 加大了库存量，以减少上游供应链的影响；（2）从 2020 年疫情开始后，国际物流的时间周 期加长、发运量减少，针对这一情况，公司加快了出口发运的时间频次，采用多批次、小批 量的方法进行发运。 今年以来，疫情在全国各地反复出现，其中 3 月中旬到 3 月底这半个月时间的青岛疫情 比较严重，也对公司的生产管理造成了一定的影响。主要包括：（1）由于疫情管控需要， 对一些小区进行了阶段性的封闭管理，公司有部分员工不能按时到公司上班，这种情况持续 了 1-2 周。公司通过部分员工驻厂和加班的方法，克服了短期的人员缺失困难，保障了生产 的正常运行。（2）物流时间加长，包括国内和国外物流，造成公司进料和出货周期加长， 公司前期的材料库存和发运策略降低了这一不利影响。（3）公司正处于产能扩充期，青岛 疫情影响厂房建设、设备安装和新招聘 ...

| --- | --- | --- | --- | --- | |------------|---------------------------------------------------------------|---------------------------------------|-----------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

| --- | --- | --- | --- | |------------|--------------|------------|---------------| | | | | | | 来访者类型 | 特定对象调研 | 分析师会议 | 分析师会议 | | | 媒体采访 | 业绩说明会 | 新闻发布会 | | | 路演活动 | 现场参观 | 其他 电话会议 | 详见附件 来访人员姓 名、身份证 号及职务 | --- | --- | --- | --- | |------------|-----------------------------------|--------------|----------------------------------------------------------------------------------| | 接待时间 | 5 月 01 日-5 月 31 日 | 预约接待地点 | 腾讯会议、公司会议 | | 参会投资者 | 【180】人 | 接待人员 | 董事、总经理郑耀， 公司副总经理、董事 会秘书、财务总监汪 方华，证券事务代表 薛欢 | 1. 公司的内窥镜 ...

2022 年第三季度报告 证券代码：688677 证券简称：海泰新光 青岛海泰新光科技股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期 比上年同 | 年初至报告期末 | 年初至报告期 末比上年同期 | | --- | --- | --- | --- | --- | | | | 期增减变 | | 增减变动幅度 | | | | 动幅度(%) | | (%) | | 营业收入 | 143,443,201.95 | 73.88 | 339,672,960.09 | 55.77 ...

Financial Performance - The company reported a significant increase in revenue for the first half of 2022, with total revenue reaching CNY 500 million, representing a year-on-year growth of 25%[13]. - The company's operating revenue for the first half of 2022 was ¥196,229,758.14, representing a year-on-year increase of 44.74%[21]. - The net profit attributable to shareholders for the same period was ¥79,869,433.79, reflecting a year-on-year growth of 35.80%[23]. - The net profit after deducting non-recurring gains and losses increased by 72.34% year-on-year, amounting to ¥73,066,877.32[21]. - The basic earnings per share for the first half of 2022 was ¥0.92, up 24.32% compared to the previous year[22]. - The gross profit margin for the first half of 2022 was reported at 45%, a slight increase from 42% in the same period last year[13]. Research and Development - The company has invested CNY 50 million in R&D for innovative medical imaging technologies, aiming to reduce costs by 15%[13]. - Research and development expenses accounted for 12.27% of operating revenue, slightly up from 12.15% in the previous year[22]. - Total R&D investment reached ¥24,076,463.30, a significant increase of 46.19% compared to ¥16,469,029.19 in the same period last year[96]. - The company has established a comprehensive R&D management system and has a team of 106 R&D personnel, accounting for 14.17% of total employees[107]. - The company has filed 18 new patent applications and received 24 new patent grants during the reporting period[93]. Product Development and Innovation - New product development includes the launch of a next-generation imaging device, expected to enhance diagnostic accuracy by 30%[13]. - The company is expanding its product line to include 4K endoscope systems and other advanced imaging solutions, aligning with the trend of domestic substitution[35]. - The company has developed a 4K ultra-high-definition fluorescence imaging system, which has received product registration and production permits, enhancing its competitive advantage in the endoscope market[51]. - The company has developed a high-efficiency multi-band LED illumination optical design patent technology, which has been successfully applied in endoscope systems[59]. - The company has developed dual optical path 3D fluorescence endoscope technology, suitable for 10mm 3D laparoscopic systems, enhancing surgical capabilities[91]. Market Expansion and Strategy - The company is planning to expand its market presence in Southeast Asia, targeting a market share increase of 10% within the next year[13]. - The company aims to enhance its market presence by adopting a dual-brand strategy, focusing on both self-owned brands and partnerships for market promotion[37]. - The company plans to focus on the mass production of 4K fluorescence laparoscopes and the development of an automatic fogging endoscope system in the second half of 2022[112]. - The company is actively expanding its product applications in various sectors, including diagnostics, beauty equipment, and industrial laser devices, leveraging its optical technology expertise[53]. Financial Management and Investments - The company plans to use up to RMB 100 million of idle raised funds to temporarily supplement working capital, with a usage period not exceeding 12 months[194]. - The total amount of raised funds is RMB 778,852,800, with a net amount after deducting issuance costs of RMB 693,516,251.67[191]. - The company has utilized up to RMB 490 million of temporarily idle raised funds for cash management, ensuring the safety and liquidity of the investments[195]. - The company has made a new investment of CNY 29.4 million in its associate, Guoyao Xinguang Medical Technology Co., Ltd., which completed its business registration on March 25, 2022[131]. Risk Management - The management has identified potential risks related to supply chain disruptions, which could impact production timelines[13]. - The company has established a comprehensive internal control system to manage risks associated with business expansion and increased employee numbers[116]. - The company is closely monitoring international trade policies to mitigate risks related to overseas sales, which have a high export ratio[119]. Environmental Compliance - The company is not classified as a key pollutant discharge unit and adheres to environmental protection regulations[143]. - The company has implemented measures to treat wastewater, including sedimentation before connecting to municipal sewage systems[144]. - The company has adopted dust collection and exhaust treatment systems to manage air emissions from production processes[145]. - The company ensures solid waste is properly managed, with hazardous waste handled by qualified disposal companies[146]. Shareholder Commitments - The company has committed to a share lock-up period of 36 months from the date of stock listing, during which no shares can be transferred or managed by others[154]. - The company’s major shareholders and executives are required to report any share transfers and disclose reduction plans 15 days prior to selling shares[158]. - The company’s commitment to share lock-up and reduction is aimed at enhancing investor confidence and maintaining market integrity[156].

Financial Performance - The company's operating revenue for 2021 was approximately ¥309.67 million, representing a year-on-year increase of 12.53% compared to ¥275.20 million in 2020[21]. - The net profit attributable to shareholders for 2021 was approximately ¥117.73 million, reflecting a year-on-year growth of 22.19% from ¥96.35 million in 2020[21]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 94.006 million, reflecting a growth of 12.02% year-on-year[34]. - The company's total assets increased by 183.19% year-on-year to approximately ¥1.18 billion, compared to ¥417.31 million in 2020[24]. - The basic earnings per share for 2021 was ¥1.41, a decrease of 4.73% from ¥1.48 in 2020[22]. - The company's cash and cash equivalents increased significantly to CNY 723,080,364.17, representing 61.19% of total assets, up from 19.84% in the previous period, reflecting a 773.14% increase[169]. - The company achieved a main business revenue of 30,961.64 million RMB, an increase of 3,511.90 million RMB, representing a year-on-year growth of 12.79%[141]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion in 2021, representing a growth of 20% compared to the previous year[196]. - The company reported a revenue increase of 15% year-over-year, reaching $1.2 billion for the fiscal year 2021[199]. Research and Development - Research and development expenses accounted for 13.35% of operating revenue, an increase of 2.11 percentage points from 11.24% in 2020[22][24]. - The company's R&D investment in 2021 was CNY 41.343 million, an increase of 33.71% from the previous year, accounting for 13.35% of operating revenue[35]. - The total R&D investment amounted to ¥41,342,913.09, representing a 33.71% increase compared to the previous year[113]. - The company has established a clear R&D system with dedicated research organizations focusing on medical imaging technology and intelligent equipment, ensuring coordinated short-term and long-term product planning[41]. - The company has developed several advanced medical imaging systems, including a fluorescence imaging system for surgeries, which has received production licenses and is at the forefront of the industry[118]. - The company is actively researching and developing high-resolution confocal fluorescence endoscopes for early lung cancer detection, with a product registration certificate obtained on January 28, 2022[68]. - The company is focused on integrating optical technology with clinical applications, ensuring rapid response to market demands and technological changes[126]. - The company invested $50 million in R&D for new technologies, focusing on AI and machine learning applications[199]. Market Expansion and Strategy - The company plans to continue expanding its production capacity and investing in research and development to enhance its product offerings[24]. - The company is actively expanding its market presence and has developed partnerships with leading international medical device companies, enhancing its competitive edge[124]. - The company plans to establish final assembly and maintenance lines in the United States to enhance its international operations[135]. - The company aims to accelerate the development of medical endoscope series products, enhancing its existing product line to increase market share[178]. - The company plans to enhance the competitiveness of fluorescence endoscopes by developing 4K fluorescence thoracoscopes and hysteroscopes[180]. - The company is focusing on innovative applications, including 3D endoscope systems, to address clinical challenges and enhance competitive advantage[182]. - The company is exploring partnerships with local firms to enhance distribution channels, aiming to increase sales by 20% in the new regions[196]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share within the next two years[196]. Risk Management and Compliance - The company has not reported any significant risks that could materially affect its operations during the reporting period[4]. - The company has confirmed that there are no non-operating fund occupations by controlling shareholders or related parties[7]. - The company has not violated any decision-making procedures regarding external guarantees[8]. - The company has implemented a comprehensive internal control system to manage risks associated with its expanding business scale[132]. - The company adheres to ISO 13485 and ISO 9001 quality management systems for its medical devices and optical products, ensuring high-quality production standards[49]. Product Development and Innovation - The company completed the R&D and trial production of a 4K fluorescence laparoscope for U.S. clients, with plans for mass production in the second half of 2022[35]. - The company has developed and registered 4K endoscope imaging systems and laparoscopes, establishing a remote network transmission and interaction platform for 4K endoscopic images, enabling real-time surgical guidance for doctors in grassroots hospitals[65]. - The company has developed a new optical structure for endoscopes, achieving 1080P full HD resolution, with distortion below 10% compared to over 20% for conventional endoscopes[72]. - The company has successfully developed a 110° wide-angle arthroscope, surpassing the 70° field of view of mainstream domestic arthroscopes[73]. - The company has developed a depth denoising algorithm that maintains a balance between noise reduction and image detail preservation, achieving an output of 60 frames per second[99]. - The company is developing a 3D fluorescence endoscope technology, which includes dual-light path and single-light path systems, aimed at overcoming the limitations of current 3D endoscopic systems[107]. Corporate Governance - The board of directors and supervisory board members have all attended the board meeting, ensuring accountability for the report's accuracy[5]. - The company has received a standard unqualified audit report from Ernst & Young Huaming[5]. - The company has established a comprehensive quality management system, achieving certifications from major international regulatory bodies, including NMPA, FDA, and CE[128]. Shareholder Information - The total number of shares as of December 31, 2021, is 86,980,000[5]. - The total number of shares held by the chairman, Zheng Anmin, remained unchanged at 10,500,000 shares, with a total pre-tax compensation of 1.85 million CNY[194]. - The total number of shares held by the vice president, Gu Changming, remained unchanged at 120,000 shares, with a total pre-tax compensation of 910,000 CNY[195].